Sat.Jan 14, 2023 - Fri.Jan 20, 2023

article thumbnail

Driving clinical trial innovation forward with precision medicine

Pharma Phorum

Late last year, pharmaphorum spoke with AstraZeneca’s Ben Challis, VP and head of translational science and experimental medicine, cardiovascular, renal, and metabolism (CVRM), together with Magnus Jörnten-Karlsson, executive director of Unify.

article thumbnail

Large study of J&J’s HIV vaccine stopped after shot found ineffective

Bio Pharma Dive

The result from the nearly 4,000-person trial is the latest setback in a long-running effort to develop a safe and effective shot for HIV infections

Trials 286
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The impact of climate change on the pharma supply chain

Pharmaceutical Technology

Pharmaceutical supply chains are extremely vulnerable to the effects of climate change and face many challenges from sourcing to distribution.

article thumbnail

Celadon receives good manufacturing practice approval

Pharma Times

MHRA approval relates to the company’s midlands-based drug development facilities

article thumbnail

2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

article thumbnail

CDC probes possible safety risk for Pfizer's new COVID shot, sees no need to change vaccine practices

Fierce Pharma

CDC probes possible safety risk for Pfizer's new COVID shot, sees no need to change vaccine practices. zbecker. Tue, 01/17/2023 - 11:49

article thumbnail

Al Sandrock on his short retirement and taking on a biotech turnaround project

Bio Pharma Dive

In a conversation at the J.P. Morgan Healthcare conference, the longtime Biogen executive discussed his hesitance to jump back into an executive role and why an opportunity to run Voyager Therapeutics drew him in

280
280

More Trending

article thumbnail

Amvuttra recommended by NICE for amyloidosis

Pharma Times

Therapy is among the first to receive a positive draft recommendation under streamlined pilot process

116
116
article thumbnail

AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out

Fierce Pharma

AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out. Wed, 01/18/2023 - 14:00

104
104
article thumbnail

3 biotech executives on the year ahead: deals, drug pricing and the down market

Bio Pharma Dive

“What we’re experiencing now is the aftershock of the party that went on for the last three years,” said Ovid CEO Jeremy Levin in a BioPharma Dive panel that included former Sage head Jeff Jonas and biotech entrepreneur Greg Verdine

Marketing 267
article thumbnail

AI continues to gain momentum in the biopharmaceutical industry in 2023

Pharmaceutical Technology

Big Data 241
article thumbnail

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

article thumbnail

Scottish Medicines Consortium recommends Merck’s Tepmetko

Pharma Times

Therapy is the first oral MET inhibitor treatment option for certain advanced NSCLC adult patients

Medicine 117
article thumbnail

Ipsen's Onivyde proves its worth in aggressive pancreatic cancer

Fierce Pharma

Ipsen's Onivyde proves its worth in aggressive pancreatic cancer zbecker Fri, 01/20/2023 - 10:48

101
101
article thumbnail

FDA rejects Lilly Alzheimer’s drug, citing insufficient data

Bio Pharma Dive

The drugmaker had sought an accelerated approval based on promising data from a small mid-stage trial. Results from a larger study are due in the second quarter

Trials 261
article thumbnail

Hospital Universitario and Josep Carreras develop cell therapy for leukaemia

Pharmaceutical Technology

Spain’s Hospital Universitario 12 de Octubre researchers, along with the Josep Carreras Leukaemia Research Institute, have developed a new cell therapy based on STAb cells to treat a type of leukaemia.

article thumbnail

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

article thumbnail

NHS Confederation very concerned by latest industrial action

Pharma Times

Unrelenting pressure caused by strikes, flu and COVID-19 may be keeping NHS in vicious cycle

115
115
article thumbnail

UK ATMP clinical research picture remains positive despite challenging global environment

BioPharma Reporter

In 2022, the UK continued to have a signficant footprint in ATMP clinical research, with total ongoing trials increasing from 168 in 2021 to 178 in 2022, according to a new report. Markets & Regulations

Trials 102
article thumbnail

Why Wall Street shrugged at Lilly’s Alzheimer’s setback

Bio Pharma Dive

Analysts argue the FDA’s choice to decline accelerated approval for donanemab, while surprising, is not the main factor that will determine whether it eventually becomes a commercial success

245
245
article thumbnail

Moderna takes aim at global expansion plans with manufacturing ramp-up

Pharmaceutical Technology

This week, at the World Economic Forum Annual Meeting, Moderna CEO Stéphane Bancel, said the company plans to build on its exponential growth through the pandemic by expanding its operations globally over the next few years.

article thumbnail

Stada and Xbrane receive approval for Ximluci

Pharma Times

Biosimilar gains MHRA marketing authorisation for use throughout Britain

Marketing 110
article thumbnail

Bluebird extends cash runway to late 2024 with $113M raise through stock sale

Fierce Pharma

Bluebird extends cash runway to late 2024 with $113M raise through stock sale esagonowsky Thu, 01/19/2023 - 08:30

Sales 98
article thumbnail

FDA lifts hold on Astellas gene therapy for Pompe disease

Bio Pharma Dive

The regulator’s decision ends a seven-month study pause that followed a report of one participant experiencing mild symptoms of peripheral neuropathy

article thumbnail

US FDA grants Fast Track status for Avidity’s AOC 1020 to treat FSHD

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted Fast Track designation for Avidity Biosciences’ AOC 1020 to treat facioscapulohumeral muscular dystrophy (FSHD).

article thumbnail

AbbVie and Eli Lilly snub drug pricing agreement

Pharma Times

Major industry names depart leaving UK pricing deal in serious jeopardy

Drugs 111
article thumbnail

Servier, Taiho score in phase 3 colorectal cancer trial to support Lonsurf combo nod

Fierce Pharma

Servier, Taiho score in phase 3 colorectal cancer trial to support Lonsurf combo nod. kdunleavy. Wed, 01/18/2023 - 15:13

Trials 98
article thumbnail

BeiGene wins expanded approval for leukemia drug, intensifying battle with AbbVie, AstraZeneca

Bio Pharma Dive

The China-based drugmaker hopes Brukinsa’s survival data will help its drug compete with Imbruvica and Calquence

Drugs 224
article thumbnail

Inflationary storm clouds will continue to buffet global pharma industry in 2023

Pharmaceutical Technology

While the threat of high inflation is receding, its second-round effects may not quickly abate. Pharma may have to navigate a difficult path through relatively slow-to-fall inflation in regions outside the US. Untamed inflation is a top concern for the pharmaceutical industry globally in 2023.

article thumbnail

NICE recommends PTC Therapeutics’ Translarna reimbursement

Pharma Times

The NICE recommendation followed data from clinical trials and real-world evidence

article thumbnail

Martin Shkreli runs afoul of FTC for potentially skirting lifetime pharmaceutical industry ban

Fierce Pharma

Martin Shkreli runs afoul of FTC for potentially skirting lifetime pharmaceutical industry ban fkansteiner Fri, 01/20/2023 - 15:34

97
article thumbnail

With reverse merger, Elicio becomes latest biotech to bypass an IPO

Bio Pharma Dive

Elicio’s combination with Angion Biomedica comes months after it abandoned a new stock offering, and is the latest example of how the IPO slowdown has shifted startups’ plans

222
222
article thumbnail

Sun Pharma to buy Concert Pharmaceuticals for $576m

Pharmaceutical Technology

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals, in a deal valued at $576m. Under the deal terms, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

article thumbnail

NeoPhore gains additional financing for discovery pipeline

Pharma Times

The new funding package will be used to progress NeoPhore’s expanding pipeline of therapies

Packaging 101
article thumbnail

Fierce Pharma Asia—China's reimbursement round; Sun's alopecia bet; GenScript's CDMO raise

Fierce Pharma

Fierce Pharma Asia—China's reimbursement round; Sun's alopecia bet; GenScript's CDMO raise aliu Thu, 01/19/2023 - 15:53

97
article thumbnail

Editas, in next restructuring step, to sell cell therapy work to Shoreline

Bio Pharma Dive

Shoreline will acquire a preclinical NK cell therapy Editas has been developing, as well as a license to use the CRISPR biotech’s gene editing technology

article thumbnail

South Korea authorises Novavax Covid-19 vaccine as booster dose

Pharmaceutical Technology

The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above.